CIRM has funded the ALS Disease Team led by scientists at UC San Diego, The Salk Institute, and Life Technologies Corporation who aim to bring a human embryonic stem cell based ALS therapy to clinical trials within four years. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, is a progressive motor neuron disorder. Most people with ALS die within 3 to 5 years from the onset of symptoms. For more information visit CIRM's ALS disease fact sheet (www.cirm.ca.gov/ALS_facts) and The ALS Association website (www.alsa.org)